JPMorgan initiated coverage of Vor Bio (VOR) with an Overweight rating and $43 price target The firm sees the company’s telitacicept as “highly de-risked” across a range of indications. Vor is ...

JPMorgan initiated coverage of Upstream Bio (UPB) with an Overweight rating and $38 price target Upsteam’s lead asset is verekitug, a recombinant human IgG1 monoclonal antibody that binds the thymic ...